Scroll for more

Investors

 

Financial Reports & SEC Filings

Links to Sucampo’s Annual Reports, Proxy Statements and SEC Filings are below. These documents give more background on our financials and business operations.

Annual Reports

View more in the archive.

 
 

Proxy Statements

View more in the archive.

 
 

Quarterly Results

Earnings Release

10Q

 
 

SEC FILINGS

 
 
Date FiledTypeDescriptionView
February 08, 2017SC 13G/AAn amendment to the SC 13G filing
January 30, 2017SC 13GA statement of beneficial ownership of common stock by certain persons
January 09, 20178-KReport of unscheduled material events or corporate event
January 06, 20174Statement of changes in beneficial ownership of securities
January 06, 20174Statement of changes in beneficial ownership of securities
January 06, 20174Statement of changes in beneficial ownership of securities
January 06, 20174Statement of changes in beneficial ownership of securities
January 06, 20174Statement of changes in beneficial ownership of securities
December 29, 20164Statement of changes in beneficial ownership of securities
December 29, 20164Statement of changes in beneficial ownership of securities
December 29, 2016SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%
December 29, 2016SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%
December 29, 2016SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%
December 29, 2016SC 13D/AAn amendment to a SC 13D filing
December 27, 20168-KReport of unscheduled material events or corporate event
December 21, 20164Statement of changes in beneficial ownership of securities
December 19, 20168-KReport of unscheduled material events or corporate event
November 30, 20164Statement of changes in beneficial ownership of securities
November 30, 20164Statement of changes in beneficial ownership of securities
November 28, 20164Statement of changes in beneficial ownership of securities
page (1 of 35)
 

For investor inquiries please contact:

Silvia Taylor

Senior Vice President, Investor Relations and Corporate Affairs

Email: investor@sucampo.com

Phone: +1-240-223-3718

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.